Skip to content
value.today

PrognomIQ, Inc.

Total raised
$56 M
3 rounds on record
Latest round
$12 M
Jan 2026
First round on record
Aug 2024
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PrognomIQ, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2026$12 MNo. 3$10 to $50 million

PrognomIQ, Inc.: Raise no. 3, Jan 2026

Investors in this round

6 investors had bought by the notice of Jan 16, 2026: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for PrognomIQ, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian B. Koh, M.D. · Executive Officer
  • Bruce B. Wilcox, Ph.D. · Executive Officer
  • David L. Siewers · Executive Officer
  • Philip Ma, Ph.D. · Executive Officer, Director
  • Isaac B. Ro, Ph.D. · Director
  • Mark B. McClellan, M.D., Ph.D. · Director
  • Omid C. Farokhzad, M.D. · Director
  • Rajesh B. Garg, M.D. · Director
  • Tomer C. Berkovitz, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip Ma, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 16, 2026. Read the notice at the SEC.

equitySEC
Aug 2025$10 MNo. 2$10 to $50 million

PrognomIQ, Inc.: Raise no. 2, Aug 2025

Investors in this round

9 investors had bought by the notice of Aug 11, 2025: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for PrognomIQ, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian B. Koh, M.D. · Executive Officer
  • Bruce B. Wilcox, Ph.D. · Executive Officer
  • Joel Kaufman · Executive Officer
  • Philip Ma, Ph.D. · Executive Officer, Director
  • Isaac B. Ro, Ph.D. · Director
  • Mark B. McClellan, M.D., Ph.D. · Director
  • Omid C. Farokhzad, M.D. · Director
  • Rajesh B. Garg, M.D. · Director
  • Tomer C. Berkovitz, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip Ma, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 11, 2025. Read the notice at the SEC.

equity, optionsSEC
Aug 2024$34 MNo. 1$10 to $50 million

PrognomIQ, Inc.: Raise no. 1, Aug 2024

Investors in this round

10 investors had bought by the notice of Aug 26, 2024: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for PrognomIQ, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Koh, M.D. · Executive Officer
  • David Siewers · Executive Officer
  • Philip Ma, Ph.D. · Executive Officer, Director
  • Isaac Ro · Director
  • Mark McClellan, M.D., Ph.D. · Director
  • Omid Farokhzad, M.D. · Director
  • Rajesh Garg · Director
  • Tomer Berkovitz, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip Ma, Ph.D., Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 26, 2024. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PrognomIQ, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2026).

    SEC Form D · Jan 2026

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jan 2026

That is all the official record says: PrognomIQ, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in PrognomIQ, Inc.
InvestorKindAmountRoundRoleSource
T. Rowe Price Health Sciences Fund, Inc.Fund or asset manager$0 Mheldnot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT
Select Medical Technology and Devices PortfolioFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Growth Company K6 FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Fidelity Series Growth Company FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
Science & Technology FundFund or asset manager$0 Mheldnot statedHolds shares (fund report, May 2026)SEC Form N-PORT
T. Rowe Price Health Sciences PortfolioFund or asset managernot statednot statedHolds shares (fund report, Jun 2026)SEC Form N-PORT

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 10 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PrognomIQ, Inc.
NameRoleNamed in
Brian B. Koh, M.D.Executive officerJan 2026
Bruce B. Wilcox, Ph.D.Executive officerJan 2026
David L. SiewersExecutive officerJan 2026
Philip Ma, Ph.D.Executive officerJan 2026
Joel KaufmanExecutive officerAug 2025
Brian Koh, M.D.Executive officerAug 2024
David SiewersExecutive officerAug 2024
Isaac B. Ro, Ph.D.DirectorJan 2026
Mark B. McClellan, M.D., Ph.D.DirectorJan 2026
Omid C. Farokhzad, M.D.DirectorJan 2026
Philip Ma, Ph.D.DirectorJan 2026
Rajesh B. Garg, M.D.DirectorJan 2026
Tomer C. Berkovitz, Ph.D.DirectorJan 2026
Isaac RoDirectorAug 2024
Mark McClellan, M.D., Ph.D.DirectorAug 2024
Omid Farokhzad, M.D.DirectorAug 2024
Rajesh GargDirectorAug 2024
Tomer Berkovitz, Ph.D.DirectorAug 2024